KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Depreciation and Depletion: 2018-2025

Historic Depreciation and Depletion for Esperion Therapeutics (ESPR) over the last 8 years, with Sep 2025 value amounting to $26,000.

  • Esperion Therapeutics' Depreciation and Depletion changed negligibly% to $26,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $143,000, marking a year-over-year increase of 37.50%. This contributed to the annual value of $100,000 for FY2024, which is 50.00% down from last year.
  • According to the latest figures from Q3 2025, Esperion Therapeutics' Depreciation and Depletion is $26,000, which was down 3.70% from $27,000 recorded in Q2 2025.
  • In the past 5 years, Esperion Therapeutics' Depreciation and Depletion registered a high of $153,000 during Q1 2021, and its lowest value of $10,000 during Q2 2024.
  • In the last 3 years, Esperion Therapeutics' Depreciation and Depletion had a median value of $26,500 in 2023 and averaged $37,900.
  • Per our database at Business Quant, Esperion Therapeutics' Depreciation and Depletion plummeted by 80.39% in 2024 and then spiked by 170.00% in 2025.
  • Over the past 5 years, Esperion Therapeutics' Depreciation and Depletion (Quarterly) stood at $153,000 in 2021, then plummeted by 39.87% to $92,000 in 2022, then crashed by 54.35% to $42,000 in 2023, then surged by 52.38% to $64,000 in 2024, then remained steady at $26,000 in 2025.
  • Its Depreciation and Depletion was $26,000 in Q3 2025, compared to $27,000 in Q2 2025 and $26,000 in Q1 2025.